We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
We will guide you from your first visit to the centre, allowing you to find all the departments and make the most of our facilities. Whatever the reason for your visit, we will explain how to get about the hospital.
Haemophilia is a disease that is characterised by the presence of haemorrhages, and is caused by a deficiency of a coagulation factor. Treatment consists of replacing this deficient factor.
Treatment for haemophilia consists of substituting the deficient factor in cases of acute bleeding via intravenous administration, before any aggressive examination or surgical intervention. Factor VIII or IX concentrates can be made from plasmas or by recombining those obtained using biotechnology. In mild cases, other drugs such as desmopressin, a synthetic derivative of vasopressin, can be used.
In severe haemophilia, preventive treatment must be started before the age of two or after the first haemarthrosis to avoid serious joint complications caused by repeated bleeding, and can be used as a preventive treatment of brain haemorrhages. In haemophilia A, factor VIII should be administered three days a week and two times for haemophilia B. New treatments currently in development will allow future infusions to be spaced further apart.
Plasma and recombinant factors are currently effective and safe for the control and prevention of haemorrhages. The most serious complication in treatment is the onset of an inhibitor, and it appears in 30% of cases with severe haemophilia A and between 2% and 4% of haemophilia B cases.
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to email@example.com, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.